U.S. markets open in 7 hours 3 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
212.98-4.06 (-1.87%)
At close: 4:00PM EST
Sign in to post a message.
  • V
    I spent my last savings to get 5 shares of this company. When the $1400 checks arrive I will spend half on food and half on more shares. I shop at Trader Joe’s to save on groceries.
  • s
    Upgrades Robert W Baird Outperform USD 220 » USD 252
  • R
    Should be $260 minimum
  • A
    It appears the market is rotating out of small cap growth stocks into large cap value stocks due to interest rate fears. This is HUGE for VRTX. A great buying opportunity!
  • S
    Started a position today. Why not for a strong company on a big discount
  • n
    This is a great momentum stock, except most people prefer momentum in the other direction.
  • D
    I have a position as well at around the same price point. Lowest price target on this among covering analysts is 250$ a share. It is considered undervalued. That said, the downside is that Wall Street really sees this stock as stagnant and desperately in need of a catalyst. Right now, it’s a one trick pony with the Cystic Fibrosis drug therapies. I would not hold onto this forever. If I don’t start to see movement in the next few months, I will put that money something else.
  • Y
    Is 1300 shares enough?
  • O
    This CEO needs to go. Needs to be eliminated. Her resume coupled with performance screams she is a good medical officer. Not a commercial leader
  • j
    VRTX siting at huge yearly support , ark been buying , super risk reward , ill take it
  • M
    Another good day on red market. Buy now or regret later, this is $300 stock.
  • g
    It’s been holding a great base around 212 for quite some time. Great mid to long time hold.
  • V
    $CRSP conversation
    CRSP — THE $VRTX Q4 CONFERENCE CALL REPLAY is a must listen. Link? Link below! (Select “Listen to Webcast,” submit your information). One the presentation starts, feel free to jump to the 4-7 min mark of the presentation. The statements from the CEO Are absolutely FANTASTIC. https://investors.vrtx.com/events/event-details/vertex-pharmaceuticals-fourth-quarter-2020-earnings-conference-call

    Today, Elon Musk said CRSP is the future of medicine (laughing and saying you could turn yourself into a butterfly — he clearly watched the movie Human Nature). This is it. It is $CRSP
    The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
  • M
    I am long this stock however when does a CEO come out and announce he or she wants to make a transformative acquisition in the near future ?? When she is desperate to hold onto share holders , that's when. I should have sold in April when Leiden promoted her to CEO. The fact is if she was that valuable and highly regarded at Amgen they would have never let her leave in the first place. Measure her performance since April 2020 in terms of shareholder value and then you decide on your own if you want to own this company.
  • A
    Good time to get in? I'm starting my portfolio with less than 2,000 but I was thinking of getting a share here for growth. Any advice is appreciated!
  • J
    $155-$190 coming on announcement of a merger/acquisition. It will recover from there.
  • V
    $CRSP conversation
    $CRSP ties to $VRTX strengthen. Meanwhile, another red flag 🚩 at $EDIT — https://www.fiercebiotech.com/biotech/after-ditching-editas-abbvie-taps-caribou-for-new-crispr-car-t-pact
  • a
    $VRTX CEO: We are looking for “mid to late-stage" assets to buy.

    Please approach garo
  • K
    Keith S
    Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment
    February 16, 2021

    Shares of Bluebird Bio Inc. slid 34% in premarket trade Tuesday, after the biotech said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell disease after a report of a suspected unexpected serious adverse reaction of acute myeloid leukemia. The patient involved was treated more than five years ago and has not been diagnosed with AML, the company said in a statement.

  • D
    I would like to buy shares based on the fundamentals, but head and shoulder patterns are more often than not accurate.